Company Overview - Annexon is a biotech company based in Bayera, focusing on immunotherapy to treat neuroinflammatory diseases, with a mission to deliver transformative therapies for patients [2] - The company has two major registrational stage programs that target a market opportunity exceeding $10 billion and aim to treat over 10 million patients annually [2] Product Pipeline - The lead program is focused on dry Age-related Macular Degeneration (AMD) with geographic atrophy, which is a significant cause of blindness, and the drug candidate, vonaprument (ANX007), has shown substantial vision protection in affected patients [3] - The second drug candidate, tanruprubart, is aimed at treating Guillain-Barre syndrome [3]